MMP14 from BM-MSCs facilitates progression and Ara-C resistance in acute myeloid leukemia via the JAK/STAT pathway [0.03%]
来自骨髓间充质干细胞的MMP14通过JAK/STAT通路促进急性髓系白血病的进展和Ara-C耐药性
Jinxian Wu,Xinqi Li,Yin Liu et al.
Jinxian Wu et al.
Growing evidence underscores the pivotal impact of crosstalk between leukemic stem cells (LSCs) and mesenchymal stromal cells (MSCs) within their niche on leukemia initiation, progression, and therapy response. Although MMP14 plays an impor...
Dynamin2 mutations in newly diagnosed acute myeloid leukemia: clinical characteristics, and prognostic significance [0.03%]
急性髓系白血病中dynamin2基因突变的临床特征及预后意义
Kunpeng Luo,Jiayuan Chen,Wenting Wang et al.
Kunpeng Luo et al.
Acute myeloid leukemia (AML) is a highly heterogeneous myeloid malignancy which can be classified by genetic aberrations. To evaluate the impact of the dynamin 2 mutation in AML, we systematically assessed the characteristics and prognostic...
Antibody-drug conjugates in breast cancer: current evidence and future directions [0.03%]
抗体-药物结合物在乳腺癌中的应用：现有证据和未来方向
Ning Li,Lu Yang,Zixuan Zhao et al.
Ning Li et al.
Antibody-drug conjugates (ADCs) are a rapidly evolving class of antitumor drugs and have already revolutionized the treatment strategy of many hematologic and solid cancers. So far, trastuzumab emtansine (T-DM1), trastuzumab deruxtecan (T-D...
All-in-one CRISPR/Cas-engineered glucocorticoid-receptor knock-out EBV-gp350-CAR knock-in T cells are potent and resistant to dexamethasone [0.03%]
全功能CRISPR/Cas基因编辑的糖皮质激素受体敲除EBV-gp350-CAR敲入T细胞具有强大功效并对地塞米松有抵抗性
Theresa Kaeuferle,Maximilian Zwermann,Nadine Stoll et al.
Theresa Kaeuferle et al.
Background: Epstein-Barr virus (EBV) reactivation in immunocompromised patients and post-transplantation is associated with morbidity, mortality and with the onset of a variety of malignant diseases. Adoptive T-cell thera...
Disparities in the incidence, mortality and disability-adjusted life years of 33 early-onset cancer groups globally, 2012-2021: a systematic analysis [0.03%]
2012-2021年全球33组早期癌症发病率、死亡率和伤残调整寿命年的差异：系统分析
Wenxin Yan,Min Liu,Wenzhan Jing et al.
Wenxin Yan et al.
Background: The global cancer burden is rising, with early-onset cancers becoming more prevalent. We aimed to investigate the burden, trend and population disparity in 33 early-onset cancers from 2012 to 2021. ...
New exploration of KRASG12D inhibitors and the mechanisms of resistance [0.03%]
KRASG12D抑制剂的新探索及抗性机制
Ying Li,Junfeng Zhao,Yintao Li
Ying Li
The development of Kirsten rat sarcoma viral oncogene homologue (KRAS) targeted therapies has been the focus of cancer treatment. The most common mutant subtypes of KRAS driver genes are G12C, G12V, and G12D, and are associated with poor pr...
Post-translational modifications of immune checkpoints: unlocking new potentials in cancer immunotherapy [0.03%]
免疫检查点的翻译后修饰：解锁癌症免疫治疗的新潜力
Qiongjie Hu,Yueli Shi,Huang Wang et al.
Qiongjie Hu et al.
Immunotherapy targeting immune checkpoints has gained traction across various cancer types in clinical settings due to its notable advantages. Despite this, the overall response rates among patients remain modest, alongside issues of drug r...
Engineered circular RNA-based DLL3-targeted CAR-T therapy for small cell lung cancer [0.03%]
基于工程化环状RNA的DLL3靶向CAR-T治疗小细胞肺癌
Jingsheng Cai,Zheng Liu,Shaoyi Chen et al.
Jingsheng Cai et al.
Purpose: Circular RNA (circRNA) has emerged as a promising RNA therapeutic molecule due to its enhanced stability and prolonged protein expression compared to messenger RNA (mRNA). Using circRNA to construct transient Chi...
Efficacy and safety of immune checkpoint inhibitors in metastatic penile squamous cell carcinoma: a retrospective multicenter analysis [0.03%]
免疫检查点抑制剂在转移性阴茎鳞状细胞癌中的有效性和安全性：一项回顾性多中心分析
Timothy Schieber,Kelly Brunk,Anna Clennon et al.
Timothy Schieber et al.
Penile squamous cell carcinoma (PSCC) is a rare malignancy, and first-line therapy typically involves cisplatin-based chemotherapy. However, these regimens are often unsuitable for patients with poor performance status or advanced age due t...
Exosomal PD-L1 and lactate versus tissue PD-L1 as biomarkers for clinical outcomes of PD-1 Blockade plus chemotherapy in metastatic esophagogastric signet ring cell carcinoma [0.03%]
exoPD-L1和乳酸对比组织PD-L1作为预测PD-1抑制剂联合化疗治疗转移性食管胃印戒细胞癌的疗效biomarker研究
Yuanyuan Tian,Wei Shi,Jing Wang et al.
Yuanyuan Tian et al.
In this investigator-initiated, prospective, exploratory study, biomarkers predictive of clinical outcomes of first-line immune checkpoint inhibitor (ICI, nivolumab or pembrolizumab) plus XELOX(oxaliplatin and capecitabine) were identified ...